Article Figures & Data
Figures
- Fig. 1.
Patient 11 was a 57-year-old male with no cardiac risk factors, who developed chest pain and transient electrocardiogram (ECG) changes less than 2 h after combretastatin A4 phosphate (CA4P) infusion. The ECG revealed acute ST elevations in leads II, III, AVF, V4, V5, and V6, and ST depression in leads V1, V2, and V3. Serial cardiac enzymes were normal and catheterization demonstrated single-vessel distal coronary artery disease. These findings represent myocardial ischemia without injury.
- Fig. 2.
Patient 25 was a 77-year-old male with multiple risk factors for coronary artery disease but normal electrocardiogram (ECG) at baseline, who immediately after the combretastatin A4 phosphate (CA4P) infusion developed abdominal pain, bloating, diarrhea, and hypertension but denied any chest pain or pulmonary symptoms. Twenty-one h after receiving CA4P, the patient had laboratory evidence of myocardial ischemia, and the patient’s ECG demonstrated ischemic changes of inferolateral ST segment depression followed by deep and symmetric T wave inversion across V1 through V6. Cardiac catherization demonstrated severe two-vessel coronary artery disease. The patient underwent intracoronary angioplasty and stent deployment in both arteries.
Tables
- Table 1
QT and QTc intervals (in milliseconds) and heart rate (HR) in beats per minute (bpm) at baseline, and at hours 1, 2, 3, 4, and 24 post-CA4P infusion in all of the patients on our Phase I protocol of this agent at University Hospitals of Cleveland, Cleveland, OH (4) a
Ptb Baseline Hour 1 Hour 2 Hour 3 Hour 4 Hour 24 QT HR QTc QT HR QTc QT HR QTc QT HR QTc QT HR QTc QT HR QTc 1 335 93 417 360 91 443 360 84 426 360 81 418 340 93 423 2 350 94 438 360 82 421 360 86 431 370 83 435 360 85 428 360 85 428 3 360 82 421 340 83 400 355 94 444 350 95 440 355 92 440 360 78 410 4 350 90 429 390 81 453 370 93 461 360 101 467 355 96 449 385 80 445 5 365 68 389 390 65 406 375 79 430 385 72 422 380 72 416 375 63 384 6 410 67 433 400 66 420 390 81 453 375 78 428 370 78 422 370 69 397 7 400 65 416 415 54 394 400 63 410 400 78 456 400 74 444 440 58 433 8 410 59 407 405 50 370 405 58 398 405 54 384 390 74 433 390 60 390 9 350 83 412 370 76 416 355 93 442 340 108 456 340 103 445 360 81 418 10 335 91 413 360 80 416 365 75 408 370 78 422 365 85 434 340 95 428 11 395 67 417 440 47 389 425 60 425 370 100 478 335 118 470 415 61 418 12 336 95 423 350 87 421 350 88 424 345 99 443 350 104 461 340 92 421 13 350 78 399 395 80 456 380 92 471 345 110 467 345 82 403 14 370 79 425 390 67 412 390 81 453 380 98 486 350 100 452 370 69 397 15 385 79 442 450 58 442 410 81 476 390 88 472 400 86 479 400 80 462 16 390 64 403 360 74 400 370 72 405 360 97 458 360 111 490 400 60 400 17 345 103 452 340 84 402 320 117 447 270 153 431 310 132 460 325 112 444 18 360 84 426 400 66 420 400 72 438 355 88 430 350 101 454 19 330 85 393 360 73 397 350 99 450 340 95 428 360 90 441 360 86 431 20 350 86 419 355 114 489 345 115 478 330 130 486 360 84 426 21 340 99 437 370 87 446 355 109 478 360 115 498 360 115 498 340 115 471 22 400 68 426 450 58 442 420 69 450 390 81 453 400 80 462 390 71 424 23 350 86 419 360 81 418 360 86 431 360 98 460 360 101 467 360 88 436 24 360 96 455 380 76 428 350 104 461 330 101 428 360 113 480 370 106 492 25 435 60 435 420 67 444 410 78 467 390 86 467 360 96 455 460 51 424 MEAN 366.4 80.8 421.8 384.0 73.6 420.4 376.0 84.7 442.4 362.6 94.1 449.0 361.0 95.7 452.8 373.1 80.0 425.2 SD 28.6 12.9 16.70 32.9 14.9 25.4 27.6 16.1 23.0 28.3 19.4 26.2 21.3 15.8 21.9 32.6 17.1 25.4 n 25 25 25 24 24 24 24 24 24 25 25 25 24 24 24 24 24 24 -
a QT intervals were measured from 12-lead electrocardiographic tracings and corrected for heart rate using Bazett’s formula.
-
b Pt, patient.
-
Volume 10, Issue 1
